VOYAGER PAD Update: Rivaroxaban’s Absolute Ischemic Benefit in Peripheral Artery Disease Patients Undergoing Lower-Extremity Revascularization ‘Even Greater’ for Total Vascular Events
Rivaroxaban significantly reduced the otherwise high total event burden for peripheral artery disease (PAD) patients undergoing lower-extremity revascularization (LER) by 14% in the latest update from the VOYAGER PAD trial.